Journal of affective disorders · 2025
Real-world evaluation of at-home cranial electrotherapy stimulation (CES) for the management of sleep, anxiety, depression, stress, quality of life, and self-efficacy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
da Silva Ksenija Maravic, Broom Clementine, Daly Harvey, Griffiths Chris, Willis Andy, Bjekic Jovana
Аннотация
BACKGROUND: Direct-to-consumer neuromodulation technologies are transforming how sleep and mood disorders are self-managed outside clinical settings. Cranial electrotherapy stimulation (CES) is a low-intensity, portable intervention with growing accessibility but limited evidence in non-clinical populations and real-life contexts. This naturalistic cohort study investigated the effects of CES on sleep, anxiety, depression, stress, quality of life, and self-efficacy in a real-world, community-based setting.
METHODS: Sixty adults agreed to use the Alpha-Stim AID CES device daily for 21 days (40-60 min/day). Validated self-report measures were completed at baseline, day 21 (end-of-treatment), and day 42 (follow-up). A subsample (n = 27) wore actigraphy devices to monitor objective sleep changes.
RESULTS: By day 21, sleep quality significantly improved, with 48 % achieving insomnia remission and 50 % a reduction in daytime sleepiness. Actigraphy data corroborated subjective sleep improvements. Anxiety and depression remission rates were 72.3 % and 71.2 %, with improvements maintained three weeks post-intervention. Stress levels decreased, while self-efficacy, wellbeing, and quality of life improved, with moderate to large effect sizes. CES was rated as safe, acceptable, and easy to use: 48 % of participants preferred it over psychotherapy or medication.
DISCUSSION: CES is a safe, self-administered intervention that benefits sleep, mental health, and quality of life. This study presents the first actigraphy evidence of CES effects on sleep in a diverse, non-clinical population. Findings support a novel framework for accessible, non-pharmacological interventions for sleep and wellbeing with sustained impact at three-week follow-up. Results have significant implications for sleep quality and mental health, especially for populations underserved by traditional healthcare.
METHODS: Sixty adults agreed to use the Alpha-Stim AID CES device daily for 21 days (40-60 min/day). Validated self-report measures were completed at baseline, day 21 (end-of-treatment), and day 42 (follow-up). A subsample (n = 27) wore actigraphy devices to monitor objective sleep changes.
RESULTS: By day 21, sleep quality significantly improved, with 48 % achieving insomnia remission and 50 % a reduction in daytime sleepiness. Actigraphy data corroborated subjective sleep improvements. Anxiety and depression remission rates were 72.3 % and 71.2 %, with improvements maintained three weeks post-intervention. Stress levels decreased, while self-efficacy, wellbeing, and quality of life improved, with moderate to large effect sizes. CES was rated as safe, acceptable, and easy to use: 48 % of participants preferred it over psychotherapy or medication.
DISCUSSION: CES is a safe, self-administered intervention that benefits sleep, mental health, and quality of life. This study presents the first actigraphy evidence of CES effects on sleep in a diverse, non-clinical population. Findings support a novel framework for accessible, non-pharmacological interventions for sleep and wellbeing with sustained impact at three-week follow-up. Results have significant implications for sleep quality and mental health, especially for populations underserved by traditional healthcare.